Parkview Health

Parkview Health Research Repository
PCI Publications and Projects

Parkview Cancer Institute

12-19-2020

Survival benefit from immunocheckpoint inhibitors in stage IV
non-small cell lung cancer patients with brain metastases: A
National Cancer Database propensity-matched analysis.
Shinkichi Takamori
Takefumi Komiya MD
Parkview Health, takefumi.komiya@parkview.com

Emily Powell
Parkview Health, emily.powell@parkview.com

Follow this and additional works at: https://researchrepository.parkviewhealth.org/oncol
Part of the Oncology Commons

Recommended Citation
Takamori, Shinkichi; Komiya, Takefumi MD; and Powell, Emily, "Survival benefit from immunocheckpoint
inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer
Database propensity-matched analysis." (2020). PCI Publications and Projects. 50.
https://researchrepository.parkviewhealth.org/oncol/50

This Article is brought to you for free and open access by the Parkview Cancer Institute at Parkview Health
Research Repository. It has been accepted for inclusion in PCI Publications and Projects by an authorized
administrator of Parkview Health Research Repository. For more information, please contact
julie.hughbanks@parkview.com.

Received: 29 August 2020
DOI: 10.1002/cam4.3675

|

Revised: 26 October 2020

|

Accepted: 29 November 2020

ORIGINAL RESEARCH

Survival benefit from immunocheckpoint inhibitors in stage IV
non-small cell lung cancer patients with brain metastases: A
National Cancer Database propensity-matched analysis
Shinkichi Takamori1

|

1

Department of Thoracic Oncology,
National Hospital Organization Kyushu
Cancer Center, Fukuoka, Japan
2

Medical Oncology, Parkview Cancer
Institute, Fort Wayne, IN, USA
3

Parkview Research Center, Mirro Center
for Research and Innovation, Fort Wayne,
IN, USA
4

Oncology Research Program, Parkview
Cancer Institute, Fort Wayne, IN, USA
Correspondence
Takefumi Komiya, Medical Oncology,
Parkview Cancer Institute, 11050
Parkview Circle, Fort Wayne, IN 46845,
USA.
Email: takefumi.komiya@parkview.com

Takefumi Komiya2

|

Emily Powell3,4

Abstract
Immunocheckpoint inhibitors (ICIs) have become a standard pharmacological therapy in non-small cell lung cancer (NSCLC). Because brain metastases (BMs) have
historically been listed as exclusion criteria in previous clinical trials involving ICIs
in advanced NSCLC, the survival benefit from ICI in NSCLC patients with BMs
remains unclear. The National Cancer Database was queried for stage IV NSCLC patients with or without BMs between 2014 and 2015. Overall survival (OS) of stage IV
NSCLC patients who received immunotherapy and that of stage IV NSCLC patients
who did not receive immunotherapy were compared according to the presence or
absence of BMs. Multivariable logistic analyses identified the clinical characteristics
predictive of overall survival. A propensity score analysis was conducted with the aim
of adjusting the potential biases arising from the clinical characteristics. This study
included 42,512 patients with stage IV NSCLC; 11,810 patients with BMs and 30,702
patients without BMs. In univariate analysis, stage IV NSCLC patients with BMs
treated with immunotherapy had a significantly longer OS than those without immunotherapy after propensity score matching (median OS: 12.8 vs 10.1 months, hazard
ratio [HR]: 0.80, 95% confidence interval [CI]: 0.72–0.89, p < 0.0001). Multivariable
Cox modeling after propensity score matching confirmed the survival benefit from ICI
for stage IV NSCLC patients with BMs (HR: 0.75, 95% CI: 0.67–0.83, p < 0.0001).
The HR in NSCLC patients without BMs treated with ICI compared with those without ICI was 0.77 (95% CI: 0.73–0.82, p < 0.0001). Survival in stage IV NSCLC
patients with BMs was significantly improved by ICI treatment at levels comparable
to those without BMs using a retrospective database. ICI may be one of the promising
treatment options for stage IV NSCLC patients with BMs. These findings should be
validated in future prospective studies.
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IN T RO D U C T IO N

Lung cancer is one of the most fatal malignancies worldwide,
and non-small cell lung cancer (NSCLC) accounts for 85%
of lung cancer.1 Immunocheckpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) or programmed cell
death-ligand 1 (PD-L1) have been widely adopted in patients
with NSCLC.2-11 In patients with NSCLC, brain metastases (BMs) are diagnosed in approximately 20%–40% cases
during the course of the disease.12,13 However, in most previous clinical trials involving ICIs in advanced NSCLC, only
patients with stable central nervous system metastases were
eligible, and those with untreated symptomatic BMs were
excluded.2-11 The possible reasons for the exclusion criteria
included use of corticosteroids and possibility of central nervous system pseudoprogression.14,15
According to a previous clinical trial investigating the
efficacy of nivolumab in nonsquamous advanced NSCLC
(Checkmate 057), only 68 patients with BMs of total 582
patients (11.7%) were included.2 A subgroup analysis of the
Checkmate 057 trial reported that the hazard ratio (HR) for
overall survival (OS) in NSCLC patients with BMs treated
with nivolumab compared with patients with BMs treated
with docetaxel was 1.04 (95% confidence interval [CI], 0.62–
1.76). However, a subgroup analysis of the OAK trial investigating 85 patients with BMs of total 850 patients (10.0%)
showed that the HR for OS in NSCLC patients with BMs
treated with atezolizumab in comparison to patients with
BMs treated with docetaxel was 0.54 (95% CI, 0.31–0.94).3
Thus, the sample sizes of analyzed advanced NSCLC patients with BMs treated with ICIs in previous clinical trials were relatively small, and survival benefit from ICIs in
such population remains unclear. Therefore, the aim of this

study was to clarify the survival benefit from ICIs in advanced NSCLC patients with BMs using the National Cancer
Database (NCDB).
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NCDB database

The NCDB is a joint project between the Commission on
Cancer (CoC) of the American College of Surgeons and the
American Cancer Society. The CoC’s NCDB and the hospitals participating in the CoC NCDB are the source of the
deidentified data used herein; they have not verified and are
not responsible for the statistical validity of the data analysis
or the conclusions derived by the authors.
Patients with any stage IV NSCLC diagnosed and captured in the NCDB database between 2014 and 2015 were selected (n = 101,169). Of these, patients whose survival data
were available and who survived at least 30 days past the date
of diagnosis were included (n = 59,138). Patients with available status for node, brain/liver/bone metastases were then
selected (n = 43,784). Of these, patients with available status
for use of surgery, radiation, and chemotherapy were selected.
Ultimately, 42,512 patients were eligible for final analysis
with 11,810 stage IV NSCLC patients with BMs and 30,702
patients with stage IV NSCLC without BMs (Figure 1).
Clinical demographics such as age (<70 vs 70+), sex
(male vs female), race (whites vs others), insurance (yes vs
no), institutions (academic vs nonacademic), Charlson-Deyo
comorbidity score (0–1 vs 2–3), years of diagnosis (2014 vs
2015), histology (adenocarcinoma, not otherwise specified
[NOS] vs others), nodal status (N0 vs N1+), bone metastasis

Patients with any stage IV NSCLC diagnosed and captured
in the NCDB between 2014 and 2015 (n = 101,169)

Overall survival data available and OS

30 days (n = 59,138)

Status for node, brain/liver/bone metastases available (n = 43,784)

Status for use of surgery, radiation, and chemotherapy available (n = 42,512)

Stage IV NSCLC
with BMs (n = 11,810)

Treated with ICIs
(n = 840)
FIGURE 1

Treated without ICIs
(n = 10,970)

Study flow diagram of case eligibility

Stage IV NSCLC
without BMs (n = 30,702)

Treated with ICIs
(n = 3,087)

Treated without ICIs
(n = 27,615)

TAKAMORI et al.

(yes vs no), liver metastasis (yes vs no), surgery for primary
lesion (yes vs no), radiation (yes vs no), and chemotherapy
(yes vs no) were collected. Radiation includes all kinds and
for both primary tumor and BMs. In stage IV NSCLC patients with BMs (n = 11,810), 9,688 patients received radiotherapy, including 7,289 for BMs and 2,399 for others. In
stage IV NSCLC patients without BMs (n = 30,702), 10,717
patients received radiotherapy, including 265 for BMs and
10,452 for others.

|

2.2

Statistical analysis

The Kaplan-Meier curves were compared using the logrank test. The associations between ICI (yes vs no) and
clinical demographics were assessed by chi-squared test.
Univariate and multivariable Cox proportional hazards
analyses were performed using JMP® 14.0 (SAS Institute
Inc., Cary, NC, USA). A propensity score analysis was
conducted with the aim of reducing the bias of the retrospective nature of the study. In the analysis of patients
with stage IV NSCLC with BMs, the propensity scores,
which were calculated by a multivariable logistic analysis,
included the following variables: age, sex, race, institution, Charlson-Deyo score, histology, nodal status, bone
metastasis, liver metastasis, surgery for primary lesion,
radiation, and chemotherapy. The propensity score matching was performed using 1:1 nearest-neighbor matching.
In the analysis of those without BMs, the propensity scores
included the following variables: age, sex, race, CharlsonDeyo score, histology, nodal status, bone metastasis, liver
metastasis, surgery for primary lesion, radiation, and
chemotherapy. Propensity score matching analyses were
performed according to XLSTAT software guideline.
Finally, 840 matched patients with BMs from each group
were included in the survival analysis. Similarly, 3,087
matched patients without BMs from each group were analyzed. In subgroup analyses, the HR for OS and its 95% CI
after propensity score matching were provided. p < 0.05
was considered statistically significant.
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Patient characteristics

A total of 42,512 cases were selected for the analysis.
Clinical characteristics are shown in Supplemental Table S1.
In total, 3,927 (9.2%) patients received ICIs. Use of ICIs was
significantly more frequent in age <70, white race, academic
institution, Charlson-Deyo score 0–1, year of diagnosis in
2015, adenocarcinoma NOS histology, nodal status N1+,
bone metastasis, no brain metastasis, no surgery for primary
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lesion, no radiation, and chemotherapy groups per univariate
analysis (data not shown).

3.2 | Associations between administration of
ICIs and clinical factors in stage IV NSCLC
patients with and without BMs
Table 1 and Supplemental Table S2 show the relationships
between administration of ICIs and clinical factors with and
without BMs, respectively. Before propensity score matching, in stage IV NSCLC patients with BMs, ICI use was significantly more frequent in age <70, Charlson-Deyo score
0–1, year of diagnosis in 2015, adenocarcinoma NOS histology, nodal status N0, bone metastasis, no surgery for primary
lesion, radiation, and chemotherapy groups per univariate
analysis (Table 1). In stage IV NSCLC patients without
BMs, administration of ICIs was significantly more frequent in age <70, nonacademic institution, Charlson-Deyo
score 0–1, year of diagnosis in 2015, adenocarcinoma NOS
histology, nodal status N1+, bone metastasis, no surgery
for primary lesion, no radiation, and chemotherapy groups
per univariate analysis before propensity score matching
(Supplemental Table S2). After propensity score matching,
the distributions of the baseline patient characteristics between ICI-administered patients and the other patients were
well-balanced.

3.3 | Univariate survival analyses in stage IV
NSCLC patients according to BMs
The Kaplan-Meier curve comparing OS according to ICI status in patients with stage IV NSCLC (total cohort) is shown
in Supplemental Figure S1. Patients who received ICIs had a
significantly longer OS than those who did not (median OS:
13.3 vs 6.9 months, HR for death: 0.63 [95% CI: 0.60–0.65],
p < 0.0001). The Kaplan-Meier curves of OS in stage IV
NSCLC patients treated with ICIs according to BMs status
are shown in Figure 2. In patients with BMs, ICI-administered
patients had a significantly longer OS than the other patients
(median OS: 12.8 vs 6.1 months, HR for death: 0.62 [95%
CI: 0.57–0.67], p < 0.0001, Figure 2A). Similarly, in patients
without BMs, ICI-administered patients had a significantly
longer OS than the other patients (Figure 2B). As shown in
Figure 2C,D, these findings remained significant after propensity score matching. Stage IV NSCLC patients with BMs
treated with ICIs had a significantly longer OS than those
without ICIs after propensity score matching (median OS:
12.8 vs 10.1 months, HR for death: 0.80 [95% CI: 0.72–0.89],
p < 0.0001, Figure 2C). The HR for death in stage IV NSCLC
patients without BMs treated with ICIs compared with those
without ICIs was 0.85 (95% CI, 0.80–0.90, Figure 2D).
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TABLE 1
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Clinical characteristics of stage IV non-small cell lung cancer patients with BMs (n = 11,810)

Sex
Race
Insurance status
Institution
Charlson-Deyo
score
Year of diagnosis
Histology

Nodal status
Bone metastasis
Liver metastasis
Surgery for
primary lesion
Radiation
Chemotherapy

After propensity score matching
(n = 1,680)

Immunotherapy, n (%)

Immunotherapy, n (%)

Yes (n = 840)

Factors
Age

Before propensity score matching (n = 11,810)

No (n = 10,970)

<70

652 (78%)

7,336 (67%)

≥70

188 (22%)

3,634 (33%)

male

422 (50%)

5,582 (51%)

female

418 (50%)

5,388 (49%)

whites

718 (85%)

9,112 (83%)

others

122 (15%)

1,858 (17%)

32 (4%)

387 (4%)

uninsured
insured

808 (96%)

10,583 (96%)

academic

361 (43%)

4,370 (40%)

others

479 (57%)

6,600 (60%)

0–1

764 (91%)

9,674 (88%)

≥2

76 (9%)

1,296 (12%)

2014

368 (44%)

5,563 (51%)

2015

472 (56%)

5,407 (49%)

adenocarcinoma
NOS

638 (76%)

7,061 (64%)

others

202 (24%)

3,909 (36%)

N0

671 (80%)

8,329 (76%)

≥N1

169 (20%)

2,641 (24%)

yes

350(42%)

3,456 (32%)

no

490 (58%)

7,514 (68%)

yes

124 (15%)

1,779 (16%)

no

716(85%)

9,191 (84%)

yes

15 (2%)

336 (3%)

no

825 (98%)

10,634 (97%)

yes

746 (89%)

8,942 (82%)

no

94 (11%)

2,028 (18%)

yes

760 (90%)

6,618 (60%)

no

80 (10%)

4,352 (40%)

p value
<0.0001
0.7181
0.0711
0.6705
0.0734
0.0159

0.0001
<0.0001

0.0095
<0.0001
0.2689
0.0357

<0.0001
<0.0001

Yes (n = 840)

No
(n = 840)

p value
0.7687

652 (78%)

657 (78%)

188 (22%)

183 (22%)

422 (50%)

418 (50%)

418 (50%)

422 (50%)

718 (85%)

718 (85%)

122 (15%)

122 (15%)

32 (4%)

18 (2%)

808 (96%)

822 (98%)

361 (43%)

354 (42%)

479 (57%)

486 (58%)

764 (91%)

764 (91%)

76 (9%)

71 (9%)

368 (44%)

427 (51%)

472 (56%)

413 (49%)

638 (76%)

633 (75%)

202 (24%)

207 (25%)

671 (80%)

675 (80%)

169 (20%)

169 (20%)

350(42%)

346 (41%)

490 (58%)

494 (59%)

124 (15%)

115 (14%)

716(85%)

725 (86%)

15 (2%)

15 (2%)

825 (98%)

825 (98%)

746 (89%)

750 (89%)

94 (11%)

90 (11%)

760 (90%)

760 (90%)

80 (10%)

80 (10%)

0.8453
1.0000
0.0440
0.7298
0.6937

0.0039
0.7762

0.8068
0.8430
0.5296
1.0000

0.7547
1.0000

Abbreviations: BM, brain metastasis; NOS, not otherwise specified.

3.4 | Univariate and multivariable
analyses of OS in stage IV NSCLC patients
according to BMs
The results of univariate and multivariable analyses for OS in
stage IV NSCLC patients with and without BMs are shown
in Table 2 and Supplemental Table S2, respectively. Before
propensity score matching, ICI was an independent factor
for predicting longer OS (HR for death: 0.70 [95% CI: 0.65–
0.77], p < 0.0001, Ta). After propensity score matching,

multivariable analysis of OS in stage IV NSCLC patients
with BMs demonstrated that younger age, female, races other
than white, academic institution, Charlson-Deyo score 0–1,
adenocarcinoma NOS histology, no bone metastasis, no liver
metastasis, chemotherapy, and ICI were independent predictors for longer OS (HR for death with ICI: 0.75 [95% CI:
0.67–0.83], p < 0.0001, Table 2). In patients with stage IV
NSCLC patients without BMs, multivariable analysis of OS
before propensity score matching revealed that ICI was an independent factor for predicting longer OS (HR for death: 0.73
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Survival Probability

Immunotherapy (+) (n=840)
Immunotherapy ( ) (n=10,970)

(b)

Log-Rank P<0.0001
HR=0.62 (0.57-0.67)
mOS=12.8 vs. 6.1 months

P<0.0001
HR=0.64 (0.61-0.67)
mOS=13.3 vs. 7.2 months

Months
No. at risk 0M
6M 12M 18M 24M 30M
IO (+)
840
639
406
237
138
57
IO ( )
10,970 5,304 2,999 1,839 1,087 554
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Immunotherapy (+) (n=3,087)
Immunotherapy ( ) (n=27,615)

Survival Probability

(a)

|

Months
36M
21
230

42M
3
51

(c)

No. at risk 0M
6M
12M 18M 24M 30M 36M 42M
IO (+)
3,087 2,380 1,467 922 527 257 103 35
IO ( )
27,615 14,534 8,383 5,319 3,116 1,581 634 157

(d)

Immunotherapy (+) (n=3,087)
Immunotherapy ( ) (n=3,087)

Survival Probability

Survival Probability

Immunotherapy (+) (n=840)
Immunotherapy ( ) (n=840)
Log-Rank P<0.0001
HR=0.80 (0.72-0.89)
mOS=12.8 vs. 10.1 months

Log-Rank P<0.0001
HR=0.85 (0.80-0.90)
mOS=13.3 vs. 10.9 months

Months

Months
No. at risk
IO (+)
IO ( )

0M
840
840

6M
639
544

12M
406
335

18M
237
205

24M 30M
138
57
114
60

36M
21
24

42M
3
12

No. at risk 0M
6M
12M
IO (+)
3,087 2,380 1,467
IO ( )
3,087 2,052 1,251

18M 24M 30M 36M 42M
922 527 257 103 35
835 521 272 111 28

F I G U R E 2 Kaplan-Meier curves comparing overall survival in stage IV non-small cell lung cancer (NSCLC) patients treated with
immunocheckpoint inhibitors (ICIs) and that of stage IV NSCLC patients who did not receive ICIs according to brain metastasis status are shown.
(A) In patients with brain metastases, ICI-administered patients had a significantly longer overall survival than the other patients. (B) In patients
without brain metastases, ICI-administered patients had a significantly longer overall survival than the other patients. (C) After propensity score
matching, in patients with brain metastases, ICI-administered patients had a significantly longer overall survival than the other patients. (D) In
patients without brain metastases, ICI-administered patients had a significantly longer overall survival than the other patients after propensity score
matching

[95% CI: 0.70–0.76], p < 0.0001, Supplemental Table S2).
Multivariable analysis of OS after propensity score matching showed that younger age, female, races other than white,
academic institution, Charlson-Deyo score 0–1, adenocarcinoma NOS histology, nodal status N0, no bone metastasis,
no liver metastasis, surgery for primary lesion, no radiation
therapy, chemotherapy, and ICI were independent predictive
factors for longer OS (HR for death with ICI: 0.77 [95% CI:
0.73–0.82], p < 0.0001, Supplemental Table S2).

matching according to each clinical factor are shown in
Figure 3 and Supplemental Figure S2. As shown in Figure 3,
in stage IV NSCLC patients with BMs, administration of
ICIs was associated with longer OS in each subgroup analysis except for races other than white. ICI treatment was also
related to better prognosis in each group in stage IV NSCLC
patients without BMs (Supplemental Figure S2).

3.5 | Subgroup analyses for OS in stage IV
NSCLC patients according to clinical factors

In patients with many types of cancer, BMs are often difficult
concerns to be resolved due to the inadequate delivery of antitumor agents through blood-brain barrier, difficulty in access
to the BMs, and neurological symptoms resulting in a decreased performance status.16 Regarding ICIs, given that the

The results of subgroup analyses for OS in stage IV NSCLC
patients with and without BMs after propensity score

4

|

DISCUSSION
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TABLE 2
(n = 30,702)
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Clinical characteristics of stage IV non-small cell lung cancer patients without BMs before and after propensity score matching
After propensity score matching
(n = 6,174)

Immunotherapy, n (%)

Immunotherapy, n (%)

Yes
(n = 3,087)

Factors
Age

Before propensity score matching
(n = 30,702)

No
(n = 27,615)

p value
<0.0001

<70

1,957 (63%)

13,522 (49%)

≥70

1,130 (37%)

14,093 (51%)

Sex

male

1,629 (53%)

15,008 (54%)

female

1,458 (47%)

12,607 (46%)

Race

whites

2,605 (84%)

22,926 (83%)

others

482 (16%)

4689 (17%)

67 (2%)

688 (2%)

Insurance status

uninsured
insured

Institution
Charlson-Deyo
score

academic

1,122 (36%)

9,141 (33%)

1,965 (64%)

18,474 (67%)

0–1

2,785 (90%)

23,571 (85%)

302 (10%)

4,044 (15%)

2014

1,287 (42%)

14,123 (51%)

2015

1,800 (58%)

13,492 (49%)

adenocarcinoma
NOS

2,325 (75%)

14,980 (54%)

others

762 (25%)

12,635 (46%)

Nodal status

N0

722 (23%)

7,665 (28%)

≥N1

2,365 (77%)

19,950 (72%)

Bone metastasis

yes

1,455 (47%)

10,639 (39%)

no

1,632 (53%)

16,976 (61%)

Liver metastasis

yes

493 (16%)

4,418 (16%)

2,594 (84%)

23,197 (84%)

Histology

no
Surgery for primary
lesion

yes
no

Radiation
Chemotherapy

yes

83 (3%)
3,004 (97%)

954 (3%)

1,957 (63%)

1,959 (63%)
1,128 (37%)

0.0950

1,629 (53%)

1,628 (53%)

1,458 (47%)

1,459 (47%)

0.0544

2,605 (84%)

2,601 (84%)

482 (16%)

486 (16%)

67 (2%)

48 (2%)

0.2748
0.0003

932 (30%)

9,785 (35%)

2,155 (70%)

17,830 (65%)

yes

2,834 (91%)

16,907 (61%)

no

253 (9%)

10,708 (39%)

3,020 (98%)

3,039 (98%)

1,122 (36%)

1,513 (49%)

1,965 (64%)

1,574 (51%)

2,785 (90%)

2,791 (90%)

302 (10%)

296 (10%)

1,287 (42%)

1,600 (52%)

1,800 (58%)

1,487 (48%)

2,325 (75%)

2,323 (75%)

762 (25%)

764 (25%)

<0.0001

722 (23%)

717 (23%)

2,365 (77%)

2,370 (77%)

<0.0001

1,455 (47%)

1,453 (47%)

1,632 (53%)

1,634 (53%)

493 (16%)

485 (16%)

2,594 (84%)

2,602 (84%)

<0.0001

<0.0001
<0.0001

0.9674
0.0255

26,661 (97%)

no

No
(n = 3,087)

1,130 (37%)

26,927 (98%)

others

≥2
Year of diagnosis

3,020 (98%)

Yes
(n = 3,087)

83 (3%)
3,004 (97%)

<0.0001
<0.0001

86 (3%)

p value
0.9579
0.9800
0.8887
0.0737
<0.0001
0.7963

<0.0001
0.9530

0.8804
0.9593
0.7804
0.8150

3,001 (97%)

932 (30%)

932 (30%)

2,155 (70%)

2,155 (70%)

2,834 (91%)

2,833 (92%)

253 (9%)

254 (8%)

1.0000
0.9630

Abbreviations: BM, brain metastasis; NOS, not otherwise specified.

brain is an immune-privileged sanctuary,16 whether ICIs can
provoke the anti-PD-1/PD-L1 reactions at the tumor microenvironment in the brain remained unknown, even if the ICIs
could penetrate the blood-brain barrier.17-19 Additionally, in
clinical trial settings, NSCLC patients with BMs were often
underrepresented in trials because a) most patients with BMs
are excluded from trial due to specifications in the exclusion
criteria,20 and b) physician investigators were reluctant to
enroll them due to safety concerns.21 Thus, the efficacy of

ICIs in NSCLC patients with BMs had not been well elucidated. However, several recent studies have implied that T
cells and tumor-infiltrating lymphocytes can be delivered to
the brain, and were associated with improved survival and
better responses to ICIs.22-24 In a clinical setting, a previous
retrospective study investigating 409 NSCLC patients with
BMs treated with nivolumab showed that the intracranial objective response rate and disease control rate were 17% and
39%, respectively.25 In addition, the previous phase II trial
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Subgroup
Sex

<70
70
Male
Female

Race

Whites
Others

Insurance

Uninsured
Insured

Institution

Academic
Others

Age

|
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HR(95%CI)
0.82(0.73-0.93)
0.72(0.57-0.90)
0.78(0.67-0.91)
0.81(0.70-0.95)
0.76(0.68-0.86)
1.04(0.76-1.41)

Charlson score

0-1
2

Diagnosis

2014
2015

Histology

Adeno/NOS
Others

Nodal mets

N0
N1

Bone mets

Yes
No

Liver mets

Yes
No

Surgery

Yes
No

Radiation

Yes
No

Chemotherapy

Yes
No

0

0.69(0.37-1.33)
0.80(0.71-0.89)
0.77(0.65-0.91)
0.83(0.72-0.95)
0.81(0.72-0.90)
0.72(0.50-1.00)
0.90(0.77-1.05)
0.70(0.60-0.82)
0.82(0.72-0.93)
0.73(0.58-0.90)
0.76(0.59-0.97)
0.81(0.72-0.92)
0.80(0.68-0.95)
0.79(0.68-0.92)
0.77(0.58-1.01)
0.80(0.71-0.90)
0.54(0.18-1.47)
0.80(0.72-0.90)
0.82(0.73-0.92)
0.66(0.47-0.93)
0.88(0.78-0.99)
0.26(0.18-0.37)

0.25

0.5

0.75
Hazard ratio

Immunotherapy better

1

1.25

1.5

Without Immunotherapy better

F I G U R E 3 Subgroup analyses of overall survival in stage IV non-small cell lung cancer patients with brain metastases according to each
clinical factor are shown. HR, hazard ratio; NOS,, adenocarcinoma, not otherwise specified

investigating efficacy of pembrolizumab for PD-L1-positive
NSCLC patients with BMs showed that the intracranial objective response rate was 29.7%.26 Our results that ICIs contributed to significant survival benefit in stage IV NSCLC
patients with BMs were in line with the findings in these recent studies.
In this retrospective study with propensity score matching,
we demonstrated that stage IV NSCLC patients treated with
ICIs had a significantly longer OS than those without ICIs
independent of the presence or absence of BMs. In this large
cohort of stage IV NSCLC patients, 840 patients had BMs
at the beginning of treatment with ICIs. Of note, the sample
size of NSCLC patients with BMs receiving ICIs was larger
than that reported in the previous representative phase III
clinical trials (9–73 patients).2-11 The representative Phase III
clinical trials investigating NSCLC patients treated with ICIs
are summarized in Supplemental Table S3. NSCLC patients
with BMs were included in only 5.5–17.5% of the total cohort.2-10 The HRs in NSCLC patients with BMs treated with
ICIs compared with those without ICIs were available in four
previous clinical trials (Checkmate 057, KEYNOTE-024,

KEYNOTE-189, and OAK), and they were ranging from
0.36 to 1.04.2-4,27 Thus, survival benefit from ICIs in NSCLC
patients with BMs was analyzed with the small number of
patients in these previous trials, and that these results were
controversial. In this study, the multivariable survival analysis showed that the HR in NSCLC patients with BMs treated
with ICIs compared with those without ICIs was 0.75 (95%
CI: 0.67–0.83) after propensity score matching (Table 2). It is
notable that the HR in NSCLC patients without BMs treated
with ICIs in comparison to those without ICIs was 0.77 (95%
CI: 0.73–0.82). These data indicate that NSCLC patients
with BMs may be good candidates for ICIs. Our data also
suggested that ICIs improved OS in NSCLC patients with
BMs by approximately 2.7 months (Figure 2C). Given that
the median OS of stage IV NSCLC patients with BMs who
were not treated by ICIs was 10.1 months, the survival benefit
from ICIs would be clinically meaningful in this population.
Thus, ICIs are one of the promising therapeutic strategies in
stage IV NSCLC patients with BMs (Table 3).
With regard to the subgroup survival analyses, ICI was
associated with longer OS in each subgroup analysis except
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for races other than white in stage IV NSCLC patients
with BMs (Figure 2). A previous study investigating the
POPLAR and OAK trials elucidated that progression-free
survival was shorter in Asian patients compared to white
race patients (12-months survival rate: 12.9% vs 20.9%),
which was similar to our findings.28 In that study, epidermal
growth factor receptor (EGFR) mutation was investigated,
TABLE 3
matching

and a different profile in relation to EGFR mutant rates was
observed between Asian and white race patients (23.8% vs
8.5%).28 The EGFR mutational status has been reported to
be associated with negative treatment outcomes in NSCLC
patients treated with anti-PD-1 therapy.29,30 The difference
in EGFR status may at least partly explain the reason why
other races did not benefit from ICIs in comparison to

Multivariable analyses of overall survival in stage IV non-small cell lung cancer patients with BMs before and after propensity score

Factors
Age
Sex
Race
Insurance status
Institution
Charlson-Deyo score
Year of diagnosis
Histology

Nodal status
Bone metastasis
Liver metastasis
Surgery for primary
lesion
Radiation

Chemotherapy
Immunotherapy

Before propensity score matching (n = 11,810)

After propensity score matching (n = 1,680)

Univariate

Multivariable

Univariate

Multivariable

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

p value

p value

p value

p value

<70

0.70 (0.67–0.73)

0.83 (0.80–0.87)

0.79 (0.69–0.90)

0.84 (0.74–0.96)

≥70

<0.0001

<0.0001

0.0005

0.0106

female

0.84 (0.81–0.87)

0.86 (0.83–0.89)

0.86 (0.77–0.96)

0.86 (0.77–0.96)

male

<0.0001

<0.0001

0.0074

0.0085

others

0.85 (0.80–0.90)

0.85 (0.81–0.90)

0.72 (0.61–0.85)

0.77 (0.65–0.91)

whites

<0.0001

<0.0001

<0.0001

0.0021

insured

1.02 (0.92–1.14)

1.00 (0.90–1.12)

0.87 (0.65–1.20)

0.90 (0.67–1.25)

uninsured

0.7003

0.9735

0.3704

0.5277

academic

0.80 (0.77–0.83)

0.82 (0.79–0.85)

0.82 (0.73–0.91)

0.80 (0.71–0.90)

others

<0.0001

<0.0001

0.0003

0.0001

0–1

0.73 (0.69–0.78)

0.83 (0.78–0.88)

0.71 (0.59–0.86)

0.76 (0.63–0.93)

≥2

<0.0001

<0.0001

0.0006

0.0067

2015

0.95 (0.91–0.99)

0.97 (0.93–1.01)

0.97 (0.87–1.08)

0.98 (0.88–1.10)

2014

0.0074

0.1533

0.5978

0.7533

adenocarcinoma
NOS

0.78 (0.75–0.81)

0.81 (0.77–0.84)

0.79 (0.70–0.90)

0.82 (0.72–0.93)

others

<0.0001

<0.0001

0.0004

0.0029

N0

0.88 (0.84–0.92)

0.78 (0.75–0.82)

0.92 (0.80–1.05)

0.92 (0.80–1.06)

≥N1

<0.0001

<0.0001

0.2192

0.2503

no

0.81 (0.78–0.85)

0.79 (0.76–0.83)

0.74 (0.66–0.82)

0.76 (0.68–0.86)

yes

<0.0001

<0.0001

<0.0001

<0.0001

no

0.68 (0.66–0.70)

0.72 (0.69–0.77)

0.65 (0.56–0.76)

0.71 (0.61–0.83)

yes

<0.0001

<0.0001

<0.0001

<0.0001

yes

0.47 (0.41–0.53)

0.51 (0.45–0.59)

0.62 (0.37–0.96)

0.64 (0.39–1.04)

no

<0.0001

<0.0001

0.0322

0.0744

yes

0.75 (0.71–0.79)

0.98 (0.93–1.03)

0.97 (0.81–1.17)

1.01 (0.84–1.21)

no

<0.0001

0.3724

0.7466

0.9217

yes

0.38 (0.36–0.39)

0.38 (0.36–0.39)

0.61 (0.51–0.73)

0.58 (0.48–0.70)

no

<0.0001

<0.0001

<0.0001

<0.0001

yes

0.62 (0.57–0.67)

0.70 (0.65–0.77)

0.80 (0.72–0.89)

0.75 (0.67–0.83)

no

<0.0001

<0.0001

<0.0001

<0.0001

Abbreviations: BM, brain metastasis; NOS, not otherwise specified.
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white race. Excluding the races, ICI was associated with
longer OS in each subgroup analysis in stage IV NSCLC
patients with BMs. Regarding the survival benefit from radiotherapy in stage IV NSCLC patients with BMs receiving ICI, the subgroup analysis of OS according to radiation
in stage IV NSCLC patients with BMs showed that the
HR in patients who had received radiotherapy and treated
with ICI compared with those without ICI was 0.82 (95%
CI: 0.73–0.92). Given that the HR in stage IV NSCLC patients who had not received radiotherapy and treated with
ICI compared with those without ICI was 0.66 (95% CI:
0.47–0.93), the interaction between radiation and ICI was
not suggested in this study.
There are some limitations in association with our
study. First, NCDB lack several prognostic factors including patients’ performance status, use of corticosteroids, and
second/third line treatments. These potential confounding
factors may affect the patients’ survival. However, to the
best of our knowledge, this study reports the largest collection of NSCLC patients with BMs treated with ICIs.
Second, in this study, how to identify the stage IV NSCLC
patients who will benefit from ICI treatment remains unknown. Previous studies have suggested several potential
predictive biomarkers for efficacy of ICIs on BMs from
NSCLC.22,31,32 Further studies investigating predictive
factors for the response to ICI treatment may clarify the
NSCLC patients with BMs who will benefit from such
treatment.
In conclusion, this study suggests that survival in stage IV
NSCLC patients with BMs was significantly improved by ICI
treatment at levels comparable to those without BMs using a
retrospective database. ICI may be one of the promising treatment options for stage IV NSCLC patients with BMs. These
findings should be validated in future prospective studies.
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